Ryvu Therapeutics (RVU.WA) Stock Price
Ryvu Therapeutics Price
Revenue has compounded at 13.9% per year over the past 15 years to 62.25 M PLN. Earnings per share have declined at 10.7% per year over the last 3 years. Ryvu Therapeutics's net margin stands at -162.6%, up from -706.9% several years earlier. Analysts set a median price target of 32.64 PLN, implying 110.6% above the current price. Of 8 analysts, 6 rate the stock a buy — an overall Buy consensus.
Ryvu Therapeutics stock price
Ryvu Therapeutics business model & stock analysis
Frequently asked questions about Ryvu Therapeutics
Ryvu Therapeutics SA operates under a business model focused on developing innovative therapies to address unmet medical needs. They specialize in research and development of novel small molecule drugs targeting cancer and inflammatory diseases. As a biopharmaceutical company, Ryvu Therapeutics is dedicated to discovering and advancing potential treatments through rigorous scientific methods. By leveraging their expertise in drug discovery and understanding of disease biology, they strive to deliver breakthrough medicines that can improve patient outcomes. Ryvu Therapeutics aims to bring innovative therapies to market that have the potential to transform patient care in areas where medical needs are not yet met.
Ryvu Therapeutics SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Ryvu Therapeutics SA in the market include Genmab A/S, Incyte Corporation, and Gilead Sciences, Inc. These companies are also active in the biopharmaceutical industry, focusing on developing and commercializing innovative therapies. However, Ryvu Therapeutics SA brings unique offerings to the market with its portfolio of proprietary drug candidates and therapeutic platforms. With its commitment to advancing precision oncology and targeted therapies, Ryvu Therapeutics SA distinguishes itself from its competitors and aims to make a significant impact in the field of biopharmaceuticals.
Ryvu Therapeutics SA is a biopharmaceutical company founded in 2007 in Poland. It focuses on discovering and developing innovative small molecule therapies for the treatment of various cancers. Ryvu Therapeutics SA has a strong research and development pipeline, with a particular emphasis on targeted therapies that can potentially address the underlying mechanisms driving cancer growth. The company has made significant progress in preclinical and early clinical stages, with several promising drug candidates. Ryvu Therapeutics SA aims to improve patient outcomes and contribute to the advancement of cancer treatment through its dedication to scientific excellence and innovative drug development approaches.
Ryvu Therapeutics SA has achieved several significant milestones. The company successfully completed its initial public offering (IPO) in February 2019, raising funds to support its research and development efforts. In October 2019, Ryvu Therapeutics SA entered into a collaboration agreement with an international pharmaceutical company for the development of innovative cancer therapies. Another noteworthy achievement is the advancement of its internal pipeline, particularly the progress made in the clinical development of its investigational drug candidates. These achievements demonstrate Ryvu Therapeutics SA's commitment to advancing novel therapies and establishing strategic partnerships in the field of oncology.
Ryvu Therapeutics SA is primarily present in Poland, where it is headquartered.
Ryvu Therapeutics SA is a biotechnology company that is committed to transforming patient care and addressing unmet medical needs. The company's corporate philosophy revolves around innovation, scientific excellence, and a patient-centric approach. Ryvu Therapeutics SA values the power of collaboration and partnerships, aiming to drive advancements in the field of oncology and rare diseases. With a focus on research and development, Ryvu Therapeutics SA strives to bring novel therapies to the market that have the potential to significantly improve and extend the lives of patients. This dedication to scientific discovery and a result-driven mindset defines the core values of Ryvu Therapeutics SA.
Analysts currently set an average price target of 54.50 PLN for the Ryvu Therapeutics stock (median: 32.64 PLN), implying +251.6 % versus the latest price. The consensus is based on 8 analyst ratings.
8 analysts currently rate the Ryvu Therapeutics stock: 6 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Ryvu Therapeutics to generate revenue of 130.37 M PLN and earnings per share of -0.26 PLN.
Converted at the current exchange rate, the Ryvu Therapeutics share trades at 3.54 EUR (15.50 PLN).
The Ryvu Therapeutics share (RVU.WA) is listed on 4 stock exchanges, including: London (0RKT.L), Frankfurt (9Y4.F).
Ryvu Therapeutics SA is a research-driven biotechnology company focused on developing novel therapies for cancer and inflammatory diseases. The company collaborates closely with researchers and academics to make breakthrough discoveries in oncology research and translate them into clinical applications. The business model of Ryvu Therapeutics SA is based on combining innovative research with numerous partnerships with academic institutions to develop novel drugs that can be used against cancer and inflammatory diseases. The company's goal is to improve the lives of cancer patients and expand the boundaries of medicine through the development of innovative technologies and new treatment options. To achieve this, the company has a wide range of products in the pipeline, including small molecule inhibitors, biologics, and immunotherapies. In addition to developing new treatment options, Ryvu Therapeutics SA also works closely with academic institutions to make new discoveries in oncology research and translate them into clinical applications. The company aims to attract new partners and investors to expand its business model and venture into new therapy areas. Overall, Ryvu Therapeutics SA's business model offers a wide range of products and services tailored to the needs of cancer patients. The company combines innovative research with numerous partnerships with academic institutions to make groundbreaking discoveries in oncology research and translate them into clinical applications. With a wide range of products in the pipeline and a dedicated leadership team, Ryvu Therapeutics SA is well positioned to improve the lives of cancer patients and promote the growth of the company.
The expected revenue of Ryvu Therapeutics is 130.37 M PLN. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Ryvu Therapeutics is -6.03 M PLN. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Ryvu Therapeutics is currently -59.39. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Ryvu Therapeutics stock.
The price-to-sales ratio (P/S) of Ryvu Therapeutics is currently 2.75. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Ryvu Therapeutics stock.
The Eulerpool Quality Score for Ryvu Therapeutics is 2/10.
The ISIN of Ryvu Therapeutics is PLSELVT00013. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Ryvu Therapeutics is A1JUH2. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Ryvu Therapeutics is RVU.WA. The ticker symbol is used to trade Ryvu Therapeutics shares on the stock exchange.
Ryvu Therapeutics stock
All fundamentals and in-depth analysis of Ryvu Therapeutics
Our stock analysis for Ryvu Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.